Trinity Biotech plc
NASDAQ:TRIBMedical - Diagnostics & Research
-$0.51 today
- Market cap
- $117.96M
- Beta
- 1.00
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.27
Volume 0.00M
Average 1.34M
TRIB Interest Income
Income earned on cash, deposits, and investments held by the company.
Trinity Biotech plcNASDAQ: TRIB
Interest Income · Q4 FY2025 · quarter ended Dec 2025
Interest income turns negative
Q4 FY2025 interest income was -$999, compared with $0 a year earlier. Trailing-twelve-month interest income was $997.23. Over 3 fiscal years it compounded at -10.0% a year.
Context
- Interest income amounted to 0.5% of revenue in FY2025, up 0.5 pp from a year earlier.
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly interest income holds near -$999 or moves back toward the trailing-twelve-month quarterly average of $249.31.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 221K USD
- Year-over-year change
- —
- 4-year CAGR
- -34.8%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 221K | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 1.17M | +286.5% |
| FY2022 | 2022-12-31 | 303K | -75.2% |
| FY2021 | 2021-12-31 | 1.22M | — |
Interest Income vs competitors
How TRIB compares with its peers on the latest reported figures
No competitor Interest Income figures are available to compare.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 81.15M | 62.52M | 56.83M | 61.56M | 43.79M |
| Cost of Revenue | 54.89M | 52.73M | 37.38M | 40.11M | 26.9M |
| Gross Profit | 33.45M | 22.05M | 19.45M | 21.44M | 16.89M |
| Gross Margin | 41.2% | 35.3% | 34.2% | 34.8% | 38.6% |
| Research & Development | 4.5M | 4.14M | 4.38M | 4.54M | 3.63M |
| Selling, General & Admin | 24.68M | 29.17M | 31.15M | 28.82M | 24.67M |
| Operating Expenses | 29.52M | 32.96M | 46.5M | 42.61M | 28.3M |
| Depreciation & Amortization | 2.74M | 2.33M | 1.78M | 1.87M | 2.68M |
| EBITDA | 10.59M | (16.71M) | (24.1M) | (16.91M) | (21.38M) |
| EBITDA Margin | 13.1% | -26.7% | -42.4% | -27.5% | -48.8% |
| Operating Income | 3.94M | (15.27M) | (27.05M) | (21.17M) | (11.42M) |
| Operating Margin | 4.9% | -24.4% | -47.6% | -34.4% | -26.1% |
| Interest Income | 1.22M | 303K | 1.17M | 0 | 221K |
| Interest Expense | 7.1M | 24.73M | 10.15M | 9.57M | 13.11M |
| Other Income / Expenses | (5.86M) | (24.43M) | (9.88M) | (9.57M) | (25.76M) |
| Income Before Tax | (1.92M) | (43.78M) | (36.93M) | (30.73M) | (37.18M) |
| Pre-Tax Margin | -2.4% | -70.0% | -65.0% | -49.9% | -84.9% |
| Income Tax Expense | (74K) | (194K) | (59K) | 486K | 199K |
| Net Income | 875K | (41M) | (24.02M) | (31.79M) | (37.38M) |
| Net Margin | 1.1% | -65.6% | -42.3% | -51.6% | -85.4% |
| EPS (Basic) | 6.30 | (180.00) | (96.00) | (52.98) | (60.00) |
| EPS (Diluted) | 4.92 | (156.00) | (96.00) | (52.98) | (60.00) |
| Weighted Avg Shares | 139.34K | 224.9K | 255.17K | 598.65K | 619.19K |
| Weighted Avg Shares (Diluted) | 177.53K | 259.16K | 255.17K | 598.65K | 619.19K |
Trinity Biotech plc
NASDAQ:TRIB
Intrinsic Alpha fair value
Locked
Current Price
$5.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.